PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
4.46M / 3.59M (Avg.)
-1.65 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
259.50%
Positive 5Y CAGR while CRN.AX is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
67.41%
3Y revenue/share CAGR above 1.5x CRN.AX's 42.80%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
336.60%
OCF/share CAGR of 336.60% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
2470.48%
Positive OCF/share growth while CRN.AX is negative. John Neff might see a comparative advantage in operational cash viability.
1201.06%
Positive 3Y OCF/share CAGR while CRN.AX is negative. John Neff might see a big short-term edge in operational efficiency.
346.20%
10Y net income/share CAGR of 346.20% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
581.91%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
1255.61%
3Y net income/share CAGR above 1.5x CRN.AX's 147.71%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-90.46%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
13786.42%
5Y equity/share CAGR above 1.5x CRN.AX's 2.53%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
62.08%
3Y equity/share CAGR above 1.5x CRN.AX's 10.77%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1938.37%
3Y dividend/share CAGR of 1938.37% while CRN.AX is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.